Capstan Medical, a developer of robotic-enabled minimally invasive solutions to address heart valve disease, announced today the successful closing of an oversubscribed $110 million Series C to further advance its mission of bringing its structural heart solution to patients. The round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.
Current heart disease treatment options, typically by open heart surgery, are not viable for most patients and existing catheter-based options have high rates of patient exclusion. Capstan's minimally invasive solution seeks to overcome limitations of current treatment options by bringing together novel heart valve implants and advanced catheter technology, fully enabled through a robotic platform, to treat a broader set of patients.
"Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population," said Maggie Nixon, CEO of Capstan Medical. "We have pulled together the right people at the right time to make this happen and are energized by the incredible support of our investors."
Since its founding in 2020, Capstan Medical has built a world-class team with heart valve, implant delivery, and robotics expertise, growing to over 75 employees across engineering, operations, clinical, and regulatory. With this new funding, the team will continue to execute on its plan for expanded clinical and development work leading to upcoming pivotal trials.
